Cann Group delivers ‘modest’ growth as imports continue to frustrate by Steve Jones February 1, 2024February 1, 2024 Increased market pressure caused by overseas imports led to slower growth for Cann Group in the […]
‘Significant’ probe underway as Epsilon creditors raise ‘various matters’ by Steve Jones January 31, 2024July 11, 2024
LGP reports sales downturn but predicts a ‘re-rating’ of Australian firms amid US rescheduling report by Steve Jones January 31, 2024July 11, 2024
Shareholders reject remuneration report as Althea is dealt ‘first strike’ by Steve Jones January 31, 2024July 11, 2024
Quarterly results: Avecho; Melodiol; Bioxyne/BLS; Emyria; Ecofibre; Zelira; Elixinol; AusCann; Botanix by Steve Jones and Martin Lane January 31, 2024July 11, 2024
Administrator ponders offers for Bod assets ahead of report to creditors by Steve Jones January 30, 2024July 16, 2024
‘We have to do something, we can’t just sit on our hands’ by Steve Jones January 30, 2024July 16, 2024
Coming up trumps: how Australian patients are reaping the rewards of a $50 bet by Steve Jones January 24, 2024July 16, 2024
Hunt for Medlab buyer drew ‘bottom feeders’, says MD as plan unfolds to deliver shareholder return by Steve Jones January 17, 2024July 11, 2024
SAS-B deep dive: more women turn to flower and anxiety on the rise as cannabis sands continue to shift by Steve Jones January 17, 2024July 11, 2024
